Literatur
- 1
Boazhang T, Kaining Z, Jingxing K. et al .
Infection with human immunodeficiency virus and hepatitis
viruses in Chinese drug addicts.
Epidemiol
Infect.
1997;
119
343-347
- 2
Tailor A, Goldberg D, Hutchinson S. et al .
Prevalence of hepatitis C virus infection among injecting
drug users in Glasgow 1990-1996: are current harm reduction strategies
working?.
J
Infect.
2000;
40
176-183
- 3
Galeazzi B, Tufano A, Barbierato E. et al .
Hepatitis C virus infection in Italian intravenous drug
users: epidemiological and clinical
aspects.
Liver.
1995;
15
209-212
- 4
West H, Worm A M, Jensen B L. et al .
Hepatitis C virus antibodies in homosexuell men and
intravenous drug users in
Denmark.
Infection.
1993;
21
115-117
- 5
Backmund M, Meyer K, Von
Zielonka M.
Prävalenzdaten zu Hepatitis B und C bei
Drogenabhängigen in
München.
Suchtmed.
2001;
1
21-24
- 6
EASL International Consensus Conference on Hepatitis C:
consensus statement.
J
Hepatol.
1999;
31 (Suppl.
1)
3
- 7
CDC .
Recommendations for Prevention and Control of Hepatitis C
Virus (HCV) infection and HCV-related
disease.
MMWR.
1998;
47
1-39
- 8
Hopf U, Niederau C, Kleber G. et al .
Behandlung der chronischen Virushepatitis B/D und der akuten
und chronischen Virushepatitis C. Konsens der Deutschen Gesellschaft für
Verdauungs- und Stoffwechselkrankheiten.
Z
Gastroenterol.
1997;
35
971-986
- 9
Gölz J.
Therapy of hepatitis C in drug addicts. Convir 2002 European
Conference on Viral Diseases, München, May 10-12, abstr.
088.
Infection.
2002;
30 (Suppl.
1)
17
- 10
Gölz J, Klausen G, Moll A. et al .
Efficiacy, tolerance and special problems of therapy with
IFN-alpha/RBV and pegIFN-alpha/RBV in HIV-/HCV-coinfected IVDUs.
XIV
Int. AIDS Conference, Barcelona.
July 7-12,
2002;
Abstr. MoPeB3258
- 11
Mauss S, Berger F, Gölz J. et al .
Treatment of chronic hepatitis C with pegylated interferon
alfa-2b and ribavirin in patients under methadone: A prospective, controlled
study.
AASLD, Boston MA.
Nov 1-5,
2002;
Abstr
- 12
Rockstroh J, Schulz C, Mauss S. et al .
Pegylated Interferon-alpha and Ribavirin Therapy for
Hepatitis C in HIV-coinfected patients: 24 weeks results.
XIV Int.
AIDS Conference, Barcelona.
July 7-12,
2002;
Abstr. MoPeB6025
- 13
Perez-Olmeda M, Romero M, Asensi V. et al .
Efficacy and safety of combination with interferon and
ribavirin in HIV-infected patients with chronic
hepatitis.
Hepatology.
2001;
34 332A.
Abstr. 634
- 14
Backmund M, Meyer K, von
Zielonka M. et. al .
Treatment of Hepatitis C in Injection Drug
Users.
Hepatology.
2001;
34
188-193
- 15
Kostman J, Smith J, Giffen C. et al .
Interferon alfa-2b/Ribavirin combination therapy in HIV/HCV
co-infected persons: results of a multicenter randomized double-blind
controlled trial.
Hepatology.
2001;
34:
§§ 2A, Abstr. 634
- 16
Kyosawa K, Sodeyama T, Tanaka E. et al .
Interrelationship of blood transfusion, non-A, non-B
hepatitis and hepatocellular carcinoma: analysis by detection of antibaody to
hepatitis C
virus.
Hepatology.
1990;
12
671-675
- 17
Tong M J, Ell-Farra S, Reikes R. et al .
Clinical outcomes after
transfusion associated-associated hepatitis C.
N Engl J
Med.
1995;
340
1463-1468
- 18
Jaeckel E, Cornberg M, Wedemeyer H. et al .
Treatment of Acute Hepatitis C With Interferon
Alfa-2b.
N Engl J
Med.
2001;
345
1452-1457
- 19
Soriano V, Kirk O, Antunes F. et al .
The influence of hepatitis C virus (HCV) on the prognosis of
HIV-infected persons. The EuroSIDA Study.
XIII th International AIDS
Conference, Durban.
July 9-14, 2000;
Abstr.
ThOrB655
- 20
Eyster M E, Diamondstone L S, Lien J M. et al .
Natural history of hepatitis C virus infection in
multitransfused hemophiliacs. Effect of coinfection with human immunodefiency
virus.
J
AIDS.
1993;
6
602-610
- 21
Rockstroh J K, Spengler U, Sudhop T. et al .
Immunosuppression may lead to progression of hepatitis C
virus associated liver desease in hemophiliacs coinfected with
HIV.
Am J
Gastroenterol.
1996;
91
2563-2568
- 22
Gölz J, Klausen G.
Diagnostik und Therapie der akuten und chronischen Hepatitis
C bei Drogenabhängigen.
Suchttherapie 2002.
3: (Suppl.
1)
54-61
- 23
The METAVIR Cooperative Group .
Inter- and intra-observer variation in the assessment of
liver biopsy of chronic hepatitis
C.
Hepatology.
1994;
20
15-20
- 24
Bedossa P, Poynard T. for the METAVIR Cooperative Study Group .
An algorithm for the grading of activity in chronic hepatitis
C.
Hepatology.
1996;
24
289-293
- 25
Manns M P, McHutchison J G, Gordon S C. et al .
Peginterferon alfa-2b plus ribavirin compared with interferon
alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a
randomised
trial.
Lancet.
2001;
358
958-965
- 26
Fried M W, Schiffmann M L, Reddy R K. et al .
Pegylated ( 40 kDa) interferon α-2a in combination with
ribavirin: Efficacy and safety resaults from a phase III, randomized, actively
controlled, multicenter
study.
Gastroenterology.
2001;
120
(Suppl. 1)
55
- 27
Kaiser S.
Charakteristik und Studienergebnisse des Consensus
Interferons.
Suchttherapie
Suppl.
2002;
3
49-53
- 28
Schäfer M.
Neuropsychiatrische Nebenwirkungen von Interferon-alpha bei
Drogenabhängigen: Ursachen, Häufigkeit und
Therapie.
Suchttherapie
Supplement.
2002;
3
72-77
- 29
Valentine A D, Meyers C A, Kling M A. et al .
Mood and cognitive side effects of interferon-alpha
therapy.
Semin
Oncol.
1998;
25
39-47
- 30
Puoti M, Spinetti A, Ghezzi A. et al .
Mortality for liver disease in patients with HIV infection: a
cohort study.
J Acquired Immune Defic
Syndr.
2000;
24
211-217
- 31
Martin-Carbonero L, Soriano V, Valencia M E. et al .
Impact of chronic viral hepatitis on hospital admission and
mortality in HIV-infected patients.
AIDS Res Hum
Retroviruses.
2001;
21
1467-71
- 32
Bica I, McGovern B, Dhar R. et al .
Increasing mortality due to end-stage liver disease in
patients with HIV infection.
Clin Infect
Dis.
2001;
32
492-497
- 33
Cacoub P, Geffray L, Rosenthal E. et al .
Mortality among HIV-infected patients with cirrhosis or
hepatocellular carcinoma due to hepatitis C virus in French Departments of
Internal Medicine/Infectious Diseases in 1995 and 1997.
Clin Infect
Dis.
2001;
32
1207-1214
- 34
Soriano V, Sulkowski M, Bergin C. et. al .
Care of patients and HIV co-infection: recommendations from
the HIV-HCV International
Panel.
AIDS.
2002;
16
813-828
Dr. med. Jörg Gölz
Praxiszentrum Kaiserdamm
Kaiserdamm 24
14057 Berlin
